Breakthroughs that break through pain and addiction

Chromocell is developing innovative drugs to treat neuropathic and nociceptive pain without risk of addiction. 

An urgent
need

Erythromelalgia (EM) is our first indication, with orphan drug designation pending, providing both substantial market potential and faster approval. There are currently no approved drugs for EM.

 

Fast-track IND STATUS to other indications

Our lead compound is now in phase 2a studies after the FDA reviewed and approved our Phase 1 results and approach. A breakthrough designation by the FDA would enable a 2025 NDA.

A NON-OPIOID ALTERNATIVE

Our patented, selective, and potent (nM) inhibitor of human NaV1.7 has demonstrated additional efficacy in several models of pain: acute, chronic, inflammatory, visceral, post surgical, and chemotherapy induced.

“WE BELIEVE OUR LEAD COMPOUND, CC8464, WILL PROVIDE THE FOUNDATION FOR SIGNIFICANT ADVANCES IN NON-OPIOID TREATMENT OF ERYTHROMELALGIA, EYE PAIN AND NEUROPATHIC PAIN.”

Frank Knuettel II • Interim CEO & Chief Financial Officer